Lipocine Enters into an Exclusive License Agreement with Antares to Commercialize Tlando in the US
Shots:
- Lipocine to receive $11.0M up front- $5.0M as licensing fees in Jan’25 & $5.0M in Jan’26- ~$160.0M as sales-based commercial milestone based on Tlando net sales- if Antares exercises Tlando XR option & royalties on sales of Tlando
- Antares to get an option to license Tlando XR for TRT in the US on or before March 31- 2022. Upon exercise of Tlando XR option- Lipocine to receive $4.0M as license fees- clinical & regulatory milestone of ~$35.0M along with royalties
- Antares will lead all commercialization- post-marketing obligations & sourcing of Tlando in the US along with Tlando XR. Lipocine holds all rights for Ex-US territories & non-TRT indications for Tlando & Tlando XR
| Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com